UnitedHealth stock forecast for 2030: Revenue reset and Optum recovery eyes $400

Traders Union
All News
Financial News
UNH revenue decline Optum loss

Highlights

UnitedHealth trades at $293.3, down 48% from all-time highs and 15% year-to-date after the first revenue decline in a decade.
Stock could reach $350-450 by 2030 if Optum Health returns to profitability and Medicare Advantage stabilizes at 5% margins.
UNH posts first revenue decline in decade, guiding $439B (down 2%), loses 1.4M MA members, and Optum Health swings to $278M loss from $7.8B profit.

This reset is being driven by multiple issues, including problems with Medicare reimbursement, challenges in controlling medical costs, regulatory pressures, and shortcomings in the company's operational performance.

First revenue decline in decades

UnitedHealth expects 2026 revenue greater than $439 billion, a 2% year-over-year decline that reflects right-sizing across the enterprise. That comes far below the $454.6 billion analysts were expecting. CFO Wayne DeVeydt called it the first time in a decade that UnitedHealth Group has had declining revenue.

He pointed to divestitures, including U.K. and South American operations, a U.S. membership decline of more than 3 million in 2026, and the final year of V28, a Medicare coding system change translating to a $6 billion revenue hit.

Medicare Advantage loses 1.4M members

In 2026, UnitedHealthcare anticipates a loss of 1.3 million to 1.4 million Medicare Advantage members, which is more than the 1 million that was previously projected. Approximately 49.7 million people had insurance through UnitedHealthcare at the end of the previous year. According to the company's forecast, the number will drop by 2.2 million to 2.8 million in 2026.

The medical cost trend for MA came in at approximately 7.5% for 2025. The business reiterated its 2026 10% trend. Medicare Advantage's 10% medical cost trend indicates that costs are increasing at a rate that is about twice as fast as CMS reimbursement growth.

The Centers for Medicare & Medicaid Services released a proposal to raise MA payment rates by 0.09% in 2027. That proposal falls well below analysts' expectations of a 4-6% increase. A 0.09% rate increase against 7-10% medical cost inflation is effectively a funding cut.

DOJ investigations expand beyond Medicare Advantage

UnitedHealth is cooperating with a DOJ probe into its Medicare Advantage billing, centered on diagnoses that increased federal payments. The criminal investigation has widened to include Optum Rx and reimbursement practices for company-employed physicians.

A Senate Judiciary Committee review of 50,000 internal documents, led by Sen. Chuck Grassley, found UnitedHealth captured more diagnoses than any other MA insurer, resulting in higher CMS reimbursements.

Former CEO Andrew Witty exited in May 2025 and was replaced by Stephen Hemsley. In February 2026, the board amended Hemsley’s stock award, requiring him to hold net shares until May 2030 after vesting. The company declared a quarterly dividend of $2.21 per share. At $293.30, the $8.84 annual payout yields about 3%.

Analyst Anton Kharitonov, an expert at Traders Union, said, “UnitedHealth is not dealing with weak demand; it is dealing with a credibility reset. When Optum swings from $7.8 billion in profit to a loss and revenue declines for the first time in a decade, investors reprice risk fast. If management restores Medicare Advantage margins and fixes Optum, the recovery will be powerful. If not, the stock trades under a new ceiling.”

Recently, UnitedHealth collapsed from $600 to $293 after reporting its first revenue decline in a decade, with Optum Health swinging to a $278 million loss from $7.8 billion profit. Medicare Advantage lost 1.4 million members, and the medical care ratio jumped 340 basis points amid DOJ investigations and a 0.09% proposed CMS rate increase for 2019. 2027.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.